Cite
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
MLA
Vistisen, Dorte, et al. “Empagliflozin Is Associated with Lower Cardiovascular Risk Compared with Dipeptidyl Peptidase-4 Inhibitors in Adults with and without Cardiovascular Disease: EMPagliflozin CompaRative EffectIveness and SafEty (EMPRISE) Study Results from Europe and Asia.” Cardiovascular Diabetology, vol. 22, no. 1, Aug. 2023, pp. 1–12. EBSCOhost, https://doi.org/10.1186/s12933-023-01963-9.
APA
Vistisen, D., Carstensen, B., Elisabetta, P., Lanzinger, S., Tan, E. C.-H., Yabe, D., Kim, D. J., Sheu, W. H.-H., Melzer-Cohen, C., Holl, R. W., Núñez, J., Ha, K. H., Halvorsen, S., Langslet, G., Karasik, A., Nyström, T., Niskanen, L., Guleria, S., Klement, R., & Carrasco, M. (2023). Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia. Cardiovascular Diabetology, 22(1), 1–12. https://doi.org/10.1186/s12933-023-01963-9
Chicago
Vistisen, Dorte, Bendix Carstensen, Patorno Elisabetta, Stefanie Lanzinger, Elise Chia-Hui Tan, Daisuke Yabe, Dae Jung Kim, et al. 2023. “Empagliflozin Is Associated with Lower Cardiovascular Risk Compared with Dipeptidyl Peptidase-4 Inhibitors in Adults with and without Cardiovascular Disease: EMPagliflozin CompaRative EffectIveness and SafEty (EMPRISE) Study Results from Europe and Asia.” Cardiovascular Diabetology 22 (1): 1–12. doi:10.1186/s12933-023-01963-9.